1921
Volume 103, Issue 3
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Reductions in malaria morbidity have been reported following azithromycin mass drug administration (MDA) for trachoma. The recent Macrolides Oraux pour Reduire les Deces avec un Oeil sur la Resistance (MORDOR) trial reported a reduction in child mortality following biannual azithromycin MDA. Here, we investigate the effects of azithromycin MDA on malaria at the MORDOR-Malawi study site. A cluster-randomized double-blind placebo-controlled trial, with 15 clusters per arm, was conducted. House-to-house census was updated biannually, and azithromycin or placebo syrup was distributed to children aged 1–59 months for a total of four biannual distributions. At baseline, 12-month, and 24-month follow-up visits, a random sample of 1,200 children was assessed for malaria with thick and thin blood smears and hemoglobin measurement. In the community-level analysis, there was no difference in the prevalence of parasitemia (1.0% lower in azithromycin-treated communities; 95% CI: −8.2 to 6.1), gametocytemia (0.7% lower in azithromycin-treated communities; 95% CI: −2.8 to 1.5), or anemia (1.7% lower in azithromycin-treated communities; 95% CI: −8.1 to 4.6) between placebo and azithromycin communities. Further interrogation of the data at the individual level, both per-protocol (including only those who received treatment 6 months previously) and by intention-to-treat, did not identify differences in parasitemia between treatment arms. In contrast to several previous reports, this study did not show an effect of azithromycin MDA on malaria parasitemia at the community or individual levels.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution (CC-BY) License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.19-0619
2020-04-27
2020-09-22
Loading full text...

Full text loading...

/deliver/fulltext/14761645/103/3/tpmd190619.html?itemId=/content/journals/10.4269/ajtmh.19-0619&mimeType=html&fmt=ahah

References

  1. Keenan JD et al., 2018. Azithromycin to reduce childhood mortality in sub-Saharan africa. N Engl J Med 378: 15831592.
    [Google Scholar]
  2. Van Eijk A, Terlouw DJ, 2011. Azithromycin for treating uncomplicated malaria. Cochrane Database Syst Rev 2: CD006688.
    [Google Scholar]
  3. Sadiq ST, Glasgow KW, Drakeley CJ, Muller O, Greenwood BM, Mabey DC, Bailey RL, 1995. Effects of azithromycin on malariometric indices in the Gambia. Lancet 346: 881882.
    [Google Scholar]
  4. Gaynor BD et al., 2014. Impact of mass azithromycin distribution on malaria parasitemia during the low-transmission season in Niger: a cluster-randomized trial. Am J Trop Med Hyg 90: 846851.
    [Google Scholar]
  5. Hart JD, Edwards T, Burr SE, Harding-Esch EM, Takaoka K, Holland MJ, Sillah A, Mabey DC, Bailey RL, 2014. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Trop Med Int Heal 19: 207211.
    [Google Scholar]
  6. Schachterle SE, Mtove G, Levens JP, Clemens E, Shi L, Raj A, Dumler JS, Munoz B, West S, Sullivan DJ 2014. Short-term malaria reduction by single-dose azithromycin during mass drug administration for trachoma, Tanzania. Emerg Infect Dis 20: 941949.
    [Google Scholar]
  7. Arzika AM et al., 2019. Biannual mass azithromycin distributions and malaria parasitemia in pre-school children in Niger: a cluster-randomized, placebo-controlled trial. PLoS Med 16: e1002835.
    [Google Scholar]
  8. Dahl EL, Rosenthal PJ, 2007. Multiple antibiotics exert delayed effects against the Plasmodium falciparum apicoplast. Antimicrob Agents Chemother 51: 34853490.
    [Google Scholar]
  9. Bregani ER, Tien TV, Monzani V, Figini G, Manenti F, 2000. Azithromycin in the treatment of Plasmodium falciparum gametocytes: preliminary observation. Panminerva Med 42: 197199.
    [Google Scholar]
  10. Kanoh S, Rubin BK, 2010. Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin Microbiol Rev 23: 590615.
    [Google Scholar]
  11. Culić O et al., 2002. Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects. Eur J Pharmacol 450: 277289.
    [Google Scholar]
  12. National Malaria Control Programme, 2018. Malawi Malaria Indicator Survey 2017. Lilongwe, Malawi.
    [Google Scholar]
  13. National Malaria Control Programme, 2015. Malawi Malaria Indicator Survey 2014. Lilongwe, Malawi.
    [Google Scholar]
  14. Hart JD, Kalua K, Keenan JD, Lietman TM, Bailey RL, 2020. Effect of mass treatment with azithromycin on causes of death in children in Malawi: secondary analysis from the MORDOR trial. Am J Trop Med Hyg 103: 13191328.
    [Google Scholar]
  15. Teh RN, Sumbele IUN, Meduke DN, Ojong ST, Kimbi HK, 2018. Malaria parasitaemia, anaemia and malnutrition in children less than 15 years residing in different altitudes along the slope of Mount Cameroon: prevalence, intensity and risk factors. Malar J 17: 336.
    [Google Scholar]
  16. Nambiema A, Robert A, Yaya I, 2019. Prevalence and risk factors of anemia in children aged from 6 to 59 months in Togo: analysis from Togo demographic and health survey data, 2013–2014. BMC Public Health 19: 215.
    [Google Scholar]
  17. Kabaghe AN, Chipeta MG, Terlouw DJ, McCann RS, van Vugt M, Grobusch MP, Takken W, Phiri KS, 2017. Short-term changes in anemia and malaria parasite prevalence in children under 5 years during one year of repeated cross-sectional surveys in rural Malawi. Am J Trop Med Hyg 97: 15681575.
    [Google Scholar]
  18. Gao D, Amza A, Nassirou B, Kadri B, Sippl-Swezey N, Liu F, Ackley SF, Lietman TM, Porco TC, 2014. Optimal seasonal timing of oral azithromycin for malaria. Am J Trop Med Hyg 91: 936942.
    [Google Scholar]
  19. Chandramohan D et al., 2019. Effect of adding azithromycin to seasonal malaria chemoprevention. N Engl J Med 380: 21972206.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.19-0619
Loading
/content/journals/10.4269/ajtmh.19-0619
Loading

Data & Media loading...

Supplemental tables

  • Received : 22 Aug 2019
  • Accepted : 02 Feb 2020
  • Published online : 27 Apr 2020
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error